Jean de la Rosette1, Alexey Martov2, Rodolfo Hurle3, Gabriel Favre4, Charalampos Mamoulakis5, Manuel Castanheira de Oliveira6, Arnulf Stenzl7, Estefania Linares-Espinós8, Carlos R Trelles Guzmán8, Stavros Gravas9,10, Thomas Knoll11, Mustafa Yucel Boz12, Thomas Herrmann13,14, Pilar Laguna12. 1. Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. j.j.delarosette@gmail.com. 2. Department of Urology, Pletnew Moscow City Hospital, Moscow, Russia. 3. Department of Urology, IRCCS Humanitas Research Hospital, Milan, Italy. 4. Department of Urology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 5. Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, Heraklion, Crete, Greece. 6. Department of Urology, Centro Hospitalar Universitário Do Porto, Hospital de Santo António, Porto, Portugal. 7. Department of Urology, University of Tuebingen Medical Center, Tuebingen, Germany. 8. Department of Urology, La Paz University Hospital, Madrid, Spain. 9. Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. 10. Medical School, University of Cyprus, Nicosia, Cyprus. 11. Department of Urology, Klinikum Sindelfingen-Boblingen, Germany. 12. Department of Urology, Istanbul Medipol Mega University Hospital, Istanbul, Turkey. 13. Department of Urology, Spital Thurgau, AG, Switzerland. 14. Department of Urology, Hannover Medical School (MHH), Hannover, Germany.
Abstract
PURPOSE: White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance. METHODS: Twelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurrence rates and subanalysis for primary/recurrent and risk groups were planned and compared by chi-square tests and survival analyses. RESULTS: 689 patients were randomized for WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT. Of these, 64.7% had a primary tumor, 35.3% a recurrent tumor, and 4.8%, 69.2% and 26.0% a low-, intermediate-, and high-risk tumor, respectively. Overall, 60 and 65 patients, respectively, completed 18-mo follow-up, with recurrence rates of 31.0% and 25.4%, respectively (p = 0.199). In patients with primary, low-/intermediate-risk tumors, recurrence rates at 18-mo were significantly higher in the WL group compared with the IMAGE1S group (31.9% and 22.3%, respectively: p 0.035). Frequency and severity of adverse events were comparable in both treatment groups. Immediate and adjuvant intravesical instillation therapy did not differ between the groups. Potential limitations included lack of uniformity of surgical resection, central pathology review, and missing data. CONCLUSION: There was not difference in the overall recurrence rates between IMAGE1S and WL assistance 18-mo after TURBT in patients with NMIBC. However, IMAGE1S-assisted TURBT considerably reduced the likelihood of disease recurrence in primary, low/intermediate risk patients. REGISTRATION: ClinicalTrials.gov Identifier NCT02252549 (30-09-2014).
PURPOSE: White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance. METHODS: Twelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurrence rates and subanalysis for primary/recurrent and risk groups were planned and compared by chi-square tests and survival analyses. RESULTS: 689 patients were randomized for WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT. Of these, 64.7% had a primary tumor, 35.3% a recurrent tumor, and 4.8%, 69.2% and 26.0% a low-, intermediate-, and high-risk tumor, respectively. Overall, 60 and 65 patients, respectively, completed 18-mo follow-up, with recurrence rates of 31.0% and 25.4%, respectively (p = 0.199). In patients with primary, low-/intermediate-risk tumors, recurrence rates at 18-mo were significantly higher in the WL group compared with the IMAGE1S group (31.9% and 22.3%, respectively: p 0.035). Frequency and severity of adverse events were comparable in both treatment groups. Immediate and adjuvant intravesical instillation therapy did not differ between the groups. Potential limitations included lack of uniformity of surgical resection, central pathology review, and missing data. CONCLUSION: There was not difference in the overall recurrence rates between IMAGE1S and WL assistance 18-mo after TURBT in patients with NMIBC. However, IMAGE1S-assisted TURBT considerably reduced the likelihood of disease recurrence in primary, low/intermediate risk patients. REGISTRATION: ClinicalTrials.gov Identifier NCT02252549 (30-09-2014).
Authors: Hugh Mostafid; Ashish M Kamat; Siamak Daneshmand; Joan Palou; John A Taylor; James McKiernan; James Catto; Marko Babjuk; Mark Soloway Journal: Eur Urol Oncol Date: 2020-07-16
Authors: S Ozono; S Hinotsu; S Tabata; K Takashima; K Fujimoto; E Okajima; Y Hirao; Y Ohashi; H Akaza; S Fukushima Journal: Jpn J Clin Oncol Date: 2001-11 Impact factor: 3.019
Authors: Guido M Kamphuis; D Martijn de Bruin; Martin J Brandt; Thomas Knoll; Pierre Conort; Alberto Lapini; Jose L Dominguez-Escrig; Jean J M C H de la Rosette Journal: J Endourol Date: 2016-02-10 Impact factor: 2.942
Authors: Seiji Naito; Ferran Algaba; Marko Babjuk; Richard T Bryan; Ying-Hao Sun; Luc Valiquette; Jean de la Rosette Journal: Eur Urol Date: 2016-04-23 Impact factor: 20.096
Authors: H Barton Grossman; Arnulf Stenzl; Yves Fradet; Lance A Mynderse; Martin Kriegmair; J Alfred Witjes; Mark S Soloway; Alexander Karl; Maximilian Burger Journal: J Urol Date: 2012-05-12 Impact factor: 7.450
Authors: Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup Journal: Eur Urol Date: 2019-08-20 Impact factor: 20.096